{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:59:36Z","timestamp":1760147976100,"version":"build-2065373602"},"reference-count":35,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>More than 600 healthcare workers died due to COVID-19 infection until January 2022 in Ecuador. Even though the COVID-19 vaccines are safe, local and systemic reactions were reported among physicians. This study aims to analyze the adverse events of COVID-19 with an emphasis on comparing the homologous and heterologous booster doses in physicians that received three approved vaccines in Ecuador. An electronic survey was performed in Quito, Ecuador, directed at physicians who were vaccinated with the three doses of COVID-19 vaccines. A total of 210 participants were analyzed after administering any dose of the vaccines. At least one AE was identified in 60.0% (126\/210) of the sample after the first dose, 52.40% (110\/210) after the second dose, and 75.2% (158\/210) after the booster dose. The most frequent AEs were localized pain, myalgia, headache, and fever. At least one drug was used in 44.3% of the population after the first dose, 37.1% after the second dose, and 63.8% in the booster dose. Heterologous booster produces more AEs compared with homologous booster (80.1% vs. 53.8%), and 77.3% of participants reported that interfered with daily activities. Similar studies agree that reactogenicity occurs mainly with heterologous vaccination compared to homologous vaccination. This situation affected physicians\u2019 performance in daily activities and led them to use medication for the symptoms. In the future, it is recommended to perform cohort studies, where adverse events that are associated with vaccine boosters in the general population can be analyzed longitudinally, thus improving the level of evidence of the results.<\/jats:p>","DOI":"10.3390\/vaccines11030676","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T03:33:57Z","timestamp":1679024037000},"page":"676","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety Profile of Homologous and Heterologous Booster COVID-19 Vaccines in Physicians in Quito-Ecuador: A Cross-Sectional Study"],"prefix":"10.3390","volume":"11","author":[{"given":"Nancy","family":"Flores-Lastra","sequence":"first","affiliation":[{"name":"Zero Biomedical Research, Quito 170103, Ecuador"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3930-252X","authenticated-orcid":false,"given":"Josue","family":"Rivadeneira-Due\u00f1as","sequence":"additional","affiliation":[{"name":"Zero Biomedical Research, Quito 170103, Ecuador"},{"name":"Doctorado en Ciencias M\u00e9dicas, Universidad de La Frontera, Temuco 4811230, Chile"},{"name":"N\u00facleo Milenio de Sociomedicina, Santiago 7560908, Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6141-7692","authenticated-orcid":false,"given":"Luis","family":"Fuenmayor-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Zero Biomedical Research, Quito 170103, Ecuador"},{"name":"Facultad de Ciencias M\u00e9dicas, Universidad Central del Ecuador, Quito 170136, Ecuador"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenda","family":"Guayasam\u00edn-Tipanta","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias M\u00e9dicas, Universidad Central del Ecuador, Quito 170136, Ecuador"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"J\u00e1come-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Zero Biomedical Research, Quito 170103, Ecuador"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6014-1241","authenticated-orcid":false,"given":"Tamara","family":"Otzen","sequence":"additional","affiliation":[{"name":"Doctorado en Ciencias M\u00e9dicas, Universidad de La Frontera, Temuco 4811230, Chile"},{"name":"N\u00facleo Milenio de Sociomedicina, Santiago 7560908, Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Manterola","sequence":"additional","affiliation":[{"name":"Doctorado en Ciencias M\u00e9dicas, Universidad de La Frontera, Temuco 4811230, Chile"},{"name":"N\u00facleo Milenio de Sociomedicina, Santiago 7560908, Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"ref_1","unstructured":"WHO (2022, April 20). WHO Coronavirus (COVID-19) Dashboard|WHO Coronavirus (COVID-19) Dashboard with Vaccination Data, Available online: https:\/\/covid19.who.int\/."},{"key":"ref_2","unstructured":"Ministerio de Salud P\u00fablica (2022, July 28). Situaci\u00f3n Epidemiol\u00f3gica Nacional COVID-19, Ecuador, Available online: https:\/\/www.salud.gob.ec\/wp-content\/uploads\/2022\/01\/10.1.2022-epi.pdf."},{"key":"ref_3","unstructured":"COE Provincial de Pichincha (2022, July 28). Situaci\u00f3n Cantonal por COVID-19. Distrito Metropolitano de Quito, Available online: https:\/\/coe-pichincha.senescyt.gob.ec\/situacion-cantones-pichincha\/."},{"key":"ref_4","unstructured":"Valeria Heredia (2023, February 02). 8 000 Vacunas Contra el Covid-19 Llegaron a Ecuador este 20 de enero. El Comercio. Available online: https:\/\/www.elcomercio.com\/tendencias\/sociedad\/vacunas-covid19-llegaron-ecuador-quito.html."},{"key":"ref_5","unstructured":"Ministrio de Salud P\u00fablica (2023, February 03). Plan Nacional de Vacunaci\u00f3n Contra la COVID-19. Plan 9\/100, Available online: https:\/\/www.salud.gob.ec\/wp-content\/uploads\/2022\/04\/Plan-Nacional-de-Vacunacion-plan-9-100.pdf."},{"key":"ref_6","unstructured":"Ministerio de Salud P\u00fablica (2023, February 03). Inicia Fase 2 del Plan de Vacunaci\u00f3n 9\/100 en Ecuador, Available online: https:\/\/www.salud.gob.ec\/inicia-fase-2-del-plan-de-vacunacion-9-100-en-ecuador\/."},{"key":"ref_7","unstructured":"PRIMICIAS (2023, February 03). Ecuador Alcanza la Meta de Vacunar a Nueve Millones de Personas en 100 D\u00edas. Available online: https:\/\/www.primicias.ec\/noticias\/sociedad\/ecuador-nueve-millones-vacunas-covid\/."},{"key":"ref_8","unstructured":"Ministerio de Salud P\u00fablica (2023, February 03). Ma\u00f1ana Inicia Vacunaci\u00f3n de Refuerzo a Personas Mayores de 18 a\u00f1os Que Cumplieron Seis Meses de Aplicada la Segunda Dosis\u2014Ministerio de Salud P\u00fablica, Available online: https:\/\/www.salud.gob.ec\/mspmanana-inicia-vacunacion-de-refuerzo-a-personas-mayores-de-18-anos-que-cumplieron-seis-meses-de-aplicada-la-segunda-dosis\/."},{"key":"ref_9","unstructured":"WHO (2006). The World Health Report. 2006: Working Together for Health."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1136\/bmjgh-2020-003097","article-title":"Infection and mortality of healthcare workers worldwide from COVID-19: A systematic review","volume":"5","author":"Bandyopadhyay","year":"2020","journal-title":"BMJ Glob. Health"},{"key":"ref_11","unstructured":"(2022, July 28). La Federaci\u00f3n M\u00e9dica Reporta Decesos de Profesionales de la Salud por \u00d3micron. Ecuavisa. Available online: https:\/\/www.ecuavisa.com\/noticias\/ecuador\/la-federacion-medica-reporta-decesos-de-profesionales-de-la-salud-por-omicron-DJ1281757."},{"key":"ref_12","unstructured":"WHO (2022, July 26). Access and Allocation: How Will There Be Fair and Equitable Allocation of Limited Supplies?, Available online: https:\/\/www.who.int\/news-room\/feature-stories\/detail\/access-and-allocation-how-will-there-be-fair-and-equitable-allocation-of-limited-supplies."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/S0140-6736(21)01290-3","article-title":"Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination","volume":"397","author":"Wall","year":"2021","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"ref_16","unstructured":"Ministerio de Salud P\u00fablica (2022, July 26). Vacun\u00f3metro COVID-19, Available online: https:\/\/app.powerbi.com\/view?r=eyJrIjoiYTkzNTFkMmUtZmUzNi00NDcwLTg0MDEtNjFkNzhhZTg5ZWYyIiwidCI6IjcwNjIyMGRiLTliMjktNGU5MS1hODI1LTI1NmIwNmQyNjlmMyJ9&pageName=ReportSection."},{"key":"ref_17","unstructured":"CDC (2022, April 21). Selected Adverse Events Reported after COVID-19 Vaccination|CDC. Vaccines, Available online: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety\/adverse-events.html."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Nohl, A., Brune, B., Weichert, V., Standl, F., Stang, A., and Dudda, M. (2022, April 21). COVID-19: Vaccination Side Effects and Sick Leave in Frontline Healthcare-Workers-A Web-Based Survey in Germany. Available online: https:\/\/www.mdpi.com\/2076-393X\/10\/3\/411.","DOI":"10.3390\/vaccines10030411"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kitro, A., Sirikul, W., Thongkum, W., Soponpong, S., Yasamut, U., Kiratipaisarl, W., Kosai, A., Kasinrerk, W., Tayapiwatana, C., and Srithanaviboonchai, K. (2022, April 21). Dynamic of Anti-Spike Receptor Binding Domain (RBD) Levels and Short-Term Adverse Events Following a Heterologous Booster Dose of BNT162b2 after Two Doses of CoronaVac in Thai Health Care Workers. Available online: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0264410X22004388?via%3Dihub.","DOI":"10.1016\/j.vaccine.2022.04.020"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S2213-2600(21)00357-X","article-title":"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: A prospective cohort study","volume":"9","author":"Hillus","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Akbulut, S., Gokce, A., Boz, G., Saritas, H., Unsal, S., Ozer, A., Akbulut, M.S., and Colak, C. (2022). Evaluation of Vaccine Hesitancy and Anxiety Levels among Hospital Cleaning Staff and Caregivers during COVID-19 Pandemic. Vaccines, 10.","DOI":"10.3390\/vaccines10091426"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"61","author":"Altman","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"ref_23","unstructured":"(2022, December 15). Helsinki Statement. WMA Declaration of Helsinki\u2014Ethical Principles for Medical Research Involving Human Subjects. 64th WMA General Assembly. Fortaleza, Brazil. Available online: https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/."},{"key":"ref_24","unstructured":"Food and Drug Administration (2022, April 19). Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials|FDA. Center for Biologics Evaluation and Research, Editor, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical."},{"key":"ref_25","unstructured":"Organizaci\u00f3n Panamericana de la Salud (2022, December 27). Introducci\u00f3n de la Vacuna Contra la COVID-19: Orientaciones Para Determinar los Grupos Prioritarios y Elaborar la Micro-planificaci\u00f3n. 2021. Report No.: 1. Available online: https:\/\/www.campusvirtualsp.org\/es."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1080\/14760584.2022.2093722","article-title":"Reactogenicity and immunogenicity of BNT162b2 or mRNA-1273 COVID-19 booster vaccinations after two doses of BNT162b2 among healthcare workers in Japan: A prospective observational study","volume":"21","author":"Naito","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Chen, P.-Y., Wu, B.-J., Su, M.-C., Lin, Y.-H., Chiang, S.-C., Wu, J.-C., Chen, T.-J., and Chen, Y.-C. (2022). Risk Factors and Incidence Rates of Self-Reported Short-Term Adverse Events of COVID-19 Vaccine Booster Dose. Vaccines, 10.","DOI":"10.3390\/vaccines10071115"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Warkentin, L., Zeschick, N., K\u00fchlein, T., Steininger, P., \u00dcberla, K., Kaiser, I., Gall, C., Sebasti\u00e3o, M., and Hueber, S. (2023, February 05). Reactogenicity after Heterologous and homologous COVID-19 Prime-Boost Vaccination Regimens: Descriptive Interim Results of a Comparative Observational Cohort Study. Available online: https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07443-x.","DOI":"10.1186\/s12879-022-07443-x"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2021-221558","article-title":"Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: A randomised controlled trial","volume":"81","author":"Bonelli","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-022-07284-8","article-title":"Effect of gender, age and vaccine on reactogenicity and incapacity to work after COVID-19 vaccination: A survey among health care workers","volume":"22","author":"Nachtigall","year":"2022","journal-title":"BMC Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2052525","DOI":"10.1080\/21645515.2022.2052525","article-title":"Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines","volume":"18","author":"Cohen","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"19551","DOI":"10.1038\/s41598-022-23471-8","article-title":"Adverse events following administration of COVID-19 vaccines in Saudi Arabia","volume":"12","author":"Alqahtani","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3389\/fpubh.2021.756633","article-title":"Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States","volume":"9","author":"Montano","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"108906","DOI":"10.1016\/j.intimp.2022.108906","article-title":"Adverse events following COVID-19 vaccination: A systematic review and meta-analysis","volume":"109","author":"Kouhpayeh","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Villalpando, J.M.G., Tapia, S.D.J.R., Flores, G.D.C.B., Castillo, J.L.B., Rojop, I.E.J., Junco, F.I.L., Hern\u00e1ndez, V.O., Gomez, S.Q., Qui\u00f1ones, J.A.R., and Priego, C.G.G. (2023, February 05). Prevalence and Risk Factors of Adverse Effects and Allergic Reactions after COVID-19 Vaccines in a Mexican Population: An Analytical Cross-Sectional Study. Available online: https:\/\/www.mdpi.com\/2076-393X\/10\/12\/2012.","DOI":"10.3390\/vaccines10122012"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/3\/676\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:56:42Z","timestamp":1760122602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/3\/676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["vaccines11030676"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11030676","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2023,3,16]]}}}